Aclaris Therapeutics Inc (NAS:ACRS)
$ 3.96 -0.11 (-2.7%) Market Cap: 282.87 Mil Enterprise Value: 172.04 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 72/100

Aclaris Therapeutics Inc R&D Day (Virtual) Transcript

Dec 07, 2021 / 03:00PM GMT
Release Date Price: $13.22 (+4.59%)
Matthew Rothman

Good morning. I'm Matthew Rothman. Counsel for Aclaris. Before we begin our prepared remarks I would like to remind you that the various statements we make during this call about the company's future results of operations and financial position, business strategy and plans and objectives for Aclaris' future operations are considered forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties that could cause actual results to differ materially from those reflected in such statements.

These risks are described in the Risk Factors section of Aclaris' Form 10-K for the year ended December 31, 2020, and other filings Aclaris makes with the SEC from time to time. These documents are available under the SEC filings page of the Investors section of Aclaris' website at www.aclaristx.com. All of the information we provide on this call is provided as of today, and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot